Anna Døssing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Døssing has a total of 144 co-authors. Here are the top co-authors by number of shared publications:
- Robin Christensen
The Parker Institute: MSU, Copenhagen University Hospital, Frederiksberg, Copenhagen, Denmark
12 shared publications - Henning Bliddal
The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
11 shared publications - Marius Henriksen
The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark
4 shared publications Simon Tarp
Bispebjerg and Frederiksberg Hospital, University of Copenhagen, The Parker Institute, Copenhagen, Denmark
4 shared publications- Simon Tarp
The Parker Institute, Bispebjerg and Frederiksberg Hospital, University of Copenhagen, Copenhagen, Denmark
4 shared publications - Bo Chawes
COPSAC, Copenhagen Prospective Studies on Asthma in Childhood, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark
3 shared publications
Latest Publications
- Open Access
- 12 October 2026
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (4) , 100887
Association of calcium phosphate crystals with pain and inflammation among individuals with advanced knee osteoarthritis: A cross-sectional study
- 12 October 2026
- Published by Elsevier in Osteoarthritis and Cartilage Open
- Vol. 8 (4) , 100887
Open AccessAssociation of calcium phosphate crystals with pain and inflammation among individuals with advanced knee osteoarthritis: A cross-sectional study
- Open Access
- 10 July 2026
- Published by Elsevier in Osteoarthritis and Cartilage
INTENSIVE DIET OR KNEE ARTHROPLASTY FOR SEVERE KNEE OSTEOARTHRITIS: THE INKA RANDOMISED TRIAL
- 10 July 2026
- Published by Elsevier in Osteoarthritis and Cartilage
Open AccessINTENSIVE DIET OR KNEE ARTHROPLASTY FOR SEVERE KNEE OSTEOARTHRITIS: THE INKA RANDOMISED TRIAL
- Open Access
- 13 March 2026
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (4) , 264-275
Accuracy of dual-energy computed tomography (CT), ultrasound, cone-beam CT, and spectral photon-counting CT for detecting calcium crystal deposition in the osteoarthritic hand: a cross-sectional diagnostic test study
Osteoarthritis (OA) is a prevalent disease that causes significant symptoms, yet our understanding of its underlying mechanisms remains incomplete. Joint-associated calcium crystal deposits are pot...
- 13 March 2026
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 55 (4) , 264-275
Open AccessAccuracy of dual-energy computed tomography (CT), ultrasound, cone-beam CT, and spectral photon-counting CT for detecting calcium crystal deposition in the osteoarthritic hand: a cross-sectional diagnostic test study
Osteoarthritis (OA) is a prevalent disease that causes significant symptoms, yet our understanding of its underlying mechanisms remains incomplete. Joint-associated calcium crystal deposits are pot...
- 24 April 2025
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 54 (4) , 263-271
Exploratory study of predictors of decreased ability to perform activities of daily living in people living with hand osteoarthritis
People with hand osteoarthritis (OA) report decreased ability to perform activities of daily living (ADL). However, few are referred to occupational therapy by their general practitioner. This study aimed to identify clinical predictors of decreased ADL ability in people with hand OA as markers of the need for referral to occupational therapy. A cross-sectional study was conducted as an independent add-on to a randomized controlled trial of adults with hand OA (the COLOR trial). Measures of self-reported (ADL Interview) and observed (Assessment of Motor and Process Skills) ADL ability were collected. Data representing potential predictors identified by stakeholders were extracted from the COLOR trial: age, sex, symptom duration, hand OA type, grip strength, pain, stiffness, function, illness perception, and health-related quality of life. Correlational analyses and prediction models were used. Correlations between ADL ability and potential predictors in the 62 participants were low to negligible (r < 0.5). Based on root mean square error (RMSE) estimates, prediction models for observed ADL motor (RMSE = 0.3) and ADL process (RMSE = 0.2) ability were more accurate than for self-reported ADL ability (RMSE = 0.6). However, these variables only predicted observed ADL motor and ADL process ability with 16% (adjusted Rs = 0.163) and 12% (adjusted Rs = 0.120) accuracy, respectively. The findings suggest that variables representing body functions, perceived health, and quality of life do not predict ADL ability among people living with hand OA. An adequately powered study is recommended to explore this topic further.
- 24 April 2025
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 54 (4) , 263-271
Exploratory study of predictors of decreased ability to perform activities of daily living in people living with hand osteoarthritis
People with hand osteoarthritis (OA) report decreased ability to perform activities of daily living (ADL). However, few are referred to occupational therapy by their general practitioner. This study aimed to identify clinical predictors of decreased ADL ability in people with hand OA as markers of the need for referral to occupational therapy. A cross-sectional study was conducted as an independent add-on to a randomized controlled trial of adults with hand OA (the COLOR trial). Measures of self-reported (ADL Interview) and observed (Assessment of Motor and Process Skills) ADL ability were collected. Data representing potential predictors identified by stakeholders were extracted from the COLOR trial: age, sex, symptom duration, hand OA type, grip strength, pain, stiffness, function, illness perception, and health-related quality of life. Correlational analyses and prediction models were used. Correlations between ADL ability and potential predictors in the 62 participants were low to negligible (r < 0.5). Based on root mean square error (RMSE) estimates, prediction models for observed ADL motor (RMSE = 0.3) and ADL process (RMSE = 0.2) ability were more accurate than for self-reported ADL ability (RMSE = 0.6). However, these variables only predicted observed ADL motor and ADL process ability with 16% (adjusted Rs = 0.163) and 12% (adjusted Rs = 0.120) accuracy, respectively. The findings suggest that variables representing body functions, perceived health, and quality of life do not predict ADL ability among people living with hand OA. An adequately powered study is recommended to explore this topic further.
- 11 April 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (6) , 663-665
Methotrexate for osteoarthritis—Ready for clinical use and in whom?
- 11 April 2025
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 33 (6) , 663-665
Methotrexate for osteoarthritis—Ready for clinical use and in whom?
- Open Access
- 26 April 2024
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 32 (7) , 848-857
Comparative effectiveness of different placebos and comparator groups for hand osteoarthritis exploring the impact of contextual factors: A systematic review and meta-analysis of randomised trials
- 26 April 2024
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 32 (7) , 848-857
Open AccessComparative effectiveness of different placebos and comparator groups for hand osteoarthritis exploring the impact of contextual factors: A systematic review and meta-analysis of randomised trials
- Open Access
Comparative effectiveness of pharmacological interventions for hand osteoarthritis: a systematic review and network meta-analysis of randomised trials
Objective To explore the comparative effectiveness of pharmacological interventions for hand osteoarthritis (OA). Methods We systematically searched Embase, MEDLINE, and the Cochrane Central Register of Controlled Trials from inception until 26 December 2021, for randomised trials of pharmacological interventions for people with hand OA. Two reviewers independently extracted study data and assessed the risk of bias. We calculated the effect sizes for pain (standardised mean differences) using Bayesian random effects models for network meta-analysis (NMA) and pairwise meta-analysis. Based on a pre-specified protocol, we prospectively registered the study at PROSPERO, CRD42021215393. Results We included 72 trials with 7609 participants. 65 trials (n=5957) were eligible for the quantitative synthesis, investigating 29 pharmacological interventions. Oral non-steroidal anti-inflammatory drugs (NSAIDs) and oral glucocorticoids’ NMA effect sizes were −0.18 (95% credible interval −0.36 to 0.02) and −0.54 (−0.83 to −0.24), respectively, compared with placebo, and the result was consistent when limiting evidence to the pairwise meta-analysis of trials without high risk of bias. Intra-articular hyaluronate, intra-articular glucocorticoids, hydroxychloroquine, and topical NSAIDs’ NMA effect sizes were 0.22 (−0.08 to 0.51), 0.25 (0.00 to 0.51), −0.01 (−0.19 to 0.18), and −0.14 (−0.33 to 0.08), respectively, compared with placebo. Oral NSAIDs were inferior to oral glucocorticoids with an NMA effect size of 0.36 (0.01 to 0.72). No intervention was superior to placebo when stratifying for thumb and finger OA. Conclusion Oral NSAIDs and glucocorticoids are apparently effective pharmacological interventions in hand OA. Intra-articular therapies and topical NSAIDs were not superior to placebo.
Open AccessComparative effectiveness of pharmacological interventions for hand osteoarthritis: a systematic review and network meta-analysis of randomised trials
Objective To explore the comparative effectiveness of pharmacological interventions for hand osteoarthritis (OA). Methods We systematically searched Embase, MEDLINE, and the Cochrane Central Register of Controlled Trials from inception until 26 December 2021, for randomised trials of pharmacological interventions for people with hand OA. Two reviewers independently extracted study data and assessed the risk of bias. We calculated the effect sizes for pain (standardised mean differences) using Bayesian random effects models for network meta-analysis (NMA) and pairwise meta-analysis. Based on a pre-specified protocol, we prospectively registered the study at PROSPERO, CRD42021215393. Results We included 72 trials with 7609 participants. 65 trials (n=5957) were eligible for the quantitative synthesis, investigating 29 pharmacological interventions. Oral non-steroidal anti-inflammatory drugs (NSAIDs) and oral glucocorticoids’ NMA effect sizes were −0.18 (95% credible interval −0.36 to 0.02) and −0.54 (−0.83 to −0.24), respectively, compared with placebo, and the result was consistent when limiting evidence to the pairwise meta-analysis of trials without high risk of bias. Intra-articular hyaluronate, intra-articular glucocorticoids, hydroxychloroquine, and topical NSAIDs’ NMA effect sizes were 0.22 (−0.08 to 0.51), 0.25 (0.00 to 0.51), −0.01 (−0.19 to 0.18), and −0.14 (−0.33 to 0.08), respectively, compared with placebo. Oral NSAIDs were inferior to oral glucocorticoids with an NMA effect size of 0.36 (0.01 to 0.72). No intervention was superior to placebo when stratifying for thumb and finger OA. Conclusion Oral NSAIDs and glucocorticoids are apparently effective pharmacological interventions in hand OA. Intra-articular therapies and topical NSAIDs were not superior to placebo.
- 5 April 2023
- Published by Elsevier in The Lancet Rheumatology
- Vol. 5 (5) , e254-e262
Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial
- 5 April 2023
- Published by Elsevier in The Lancet Rheumatology
- Vol. 5 (5) , e254-e262
Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial
- 24 February 2020
- Vol. 182 (9)
[Elimination of hepatitis C virus in Denmark].
In Denmark, about 50% of patients with chronic hepatitis C virus (HCV) infection are undiagnosed. Since 2014, therapy containing direct-acting antivirals (DAA) has proven efficient and is available to all patients, who have a chronic HCV infection and a Danish personal identification number. The World Health Organization has a goal of elimination of viral hepatitis in 2030. Elimination of HCV in Denmark should focus on reducing HCV transmission, incidence and prevalence, combined with treatment with DAA of all infected patients. Micro-elimination strategies may play a major role, but a national strategy is lacking.
- 24 February 2020
- Vol. 182 (9)
[Elimination of hepatitis C virus in Denmark].
In Denmark, about 50% of patients with chronic hepatitis C virus (HCV) infection are undiagnosed. Since 2014, therapy containing direct-acting antivirals (DAA) has proven efficient and is available to all patients, who have a chronic HCV infection and a Danish personal identification number. The World Health Organization has a goal of elimination of viral hepatitis in 2030. Elimination of HCV in Denmark should focus on reducing HCV transmission, incidence and prevalence, combined with treatment with DAA of all infected patients. Micro-elimination strategies may play a major role, but a national strategy is lacking.